A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution

BACKGROUND: Glioblastoma patients administered standard therapies, comprising maximal surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a variable prognosis with a median overall survival of 15–16 months and a 2-year overall survival of 30%. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Abedi, Armita Armina, Grunnet, Kirsten, Christensen, Ib Jarle, Michaelsen, Signe Regner, Muhic, Aida, Møller, Søren, Hasselbalch, Benedikte, Poulsen, Hans Skovgaard, Urup, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946965/
https://www.ncbi.nlm.nih.gov/pubmed/33718145
http://dx.doi.org/10.3389/fonc.2021.597587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946965/
https://www.ncbi.nlm.nih.gov/pubmed/33718145
http://dx.doi.org/10.3389/fonc.2021.597587

Ejemplares similares